Rabbit Polyclonal CARM1/PRMT4 Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07416(LCAT Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of CARM1/PRMT4 Antibody**

Coactivator-associated arginine methyltransferase 1 (CARM1), also known as protein arginine methyltransferase 4 (PRMT4), is a member of the PRMT family that catalyzes the methylation of arginine residues on histone and non-histone proteins. It plays a critical role in transcriptional regulation, RNA splicing, DNA repair, and cellular differentiation by modulating chromatin structure and protein-protein interactions. CARM1/PRMT4 is particularly notable for its interaction with transcriptional coactivators, such as the p160 family, and its ability to methylate histone H3 at arginine 17 (H3R17me2a), a mark associated with active transcription.

CARM1/PRMT4 antibodies are essential tools for studying its expression, localization, and enzymatic activity in various biological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunoprecipitation (IP), and chromatin immunoprecipitation (ChIP) to investigate CARM1's involvement in cancer progression, stem cell regulation, and metabolic diseases. Dysregulation of CARM1 has been linked to breast cancer, leukemia, and other malignancies, making it a potential therapeutic target.

Antibodies targeting CARM1/PRMT4 are designed to recognize specific epitopes, often distinguishing between methylated and unmodified forms or different isoforms. Validation includes testing in knockout models or siRNA-treated cells to ensure specificity. Researchers rely on these antibodies to explore CARM1's dual role as a coactivator and methyltransferase, advancing understanding of epigenetic mechanisms and disease pathways.